Simone Krebs
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Simone Krebs.
Molecular Therapy | 2013
Meenakshi Hegde; Amanda Corder; Kevin Chow; Malini Mukherjee; Aidin Ashoori; Yvonne Kew; Yi Jonathan Zhang; David S. Baskin; Fatima A. Merchant; Vita S. Brawley; Tiara Byrd; Simone Krebs; Meng Fen Wu; Hao Liu; Helen E. Heslop; Stephen Gottachalk; Eric Yvon; Nabil Ahmed
Preclinical and early clinical studies have demonstrated that chimeric antigen receptor (CAR)-redirected T cells are highly promising in cancer therapy. We observed that targeting HER2 in a glioblastoma (GBM) cell line results in the emergence of HER2-null tumor cells that maintain the expression of nontargeted tumor-associated antigens. Combinational targeting of these tumor-associated antigens could therefore offset this escape mechanism. We studied the single-cell coexpression patterns of HER2, IL-13Rα2, and EphA2 in primary GBM samples using multicolor flow cytometry and immunofluorescence, and applied a binomial routine to the permutations of antigen expression and the related odds of complete tumor elimination. This mathematical model demonstrated that cotargeting HER2 and IL-13Rα2 could maximally expand the therapeutic reach of the T cell product in all primary tumors studied. Targeting a third antigen did not predict an added advantage in the tumor cohort studied. We therefore generated bispecific T cell products from healthy donors and from GBM patients by pooling T cells individually expressing HER2 and IL-13Rα2-specific CARs and by making individual T cells to coexpress both molecules. Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays (against autologous glioma cells in the case of GBM patient products) and in an orthotopic xenogeneic murine model. Further, T cells coexpressing HER2 and IL-13Rα2-CARs exhibited accentuated yet antigen-dependent downstream signaling and a particularly enhanced antitumor activity.Preclinical and early clinical studies have demonstrated that chimeric antigen receptor (CAR)-redirected T cells are highly promising in cancer therapy. We observed that targeting HER2 in a glioblastoma (GBM) cell line results in the emergence of HER2-null tumor cells that maintain the expression of nontargeted tumor-associated antigens. Combinational targeting of these tumor-associated antigens could therefore offset this escape mechanism. We studied the single-cell coexpression patterns of HER2, IL-13Rα2, and EphA2 in primary GBM samples using multicolor flow cytometry and immunofluorescence, and applied a binomial routine to the permutations of antigen expression and the related odds of complete tumor elimination. This mathematical model demonstrated that cotargeting HER2 and IL-13Rα2 could maximally expand the therapeutic reach of the T cell product in all primary tumors studied. Targeting a third antigen did not predict an added advantage in the tumor cohort studied. We therefore generated bispecific T cell products from healthy donors and from GBM patients by pooling T cells individually expressing HER2 and IL-13Rα2-specific CARs and by making individual T cells to coexpress both molecules. Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays (against autologous glioma cells in the case of GBM patient products) and in an orthotopic xenogeneic murine model. Further, T cells coexpressing HER2 and IL-13Rα2-CARs exhibited accentuated yet antigen-dependent downstream signaling and a particularly enhanced antitumor activity.
Journal of Clinical Investigation | 2016
Meenakshi Hegde; Malini Mukherjee; Zakaria Grada; Antonella Pignata; Daniel Landi; Shoba A. Navai; Amanda Wakefield; Kristen Fousek; Kevin Bielamowicz; Kevin Chow; Vita S. Brawley; Tiara Byrd; Simone Krebs; Stephen Gottschalk; Winfried S. Wels; Matthew L. Baker; Gianpietro Dotti; Maksim Mamonkin; Malcolm K. Brenner; Jordan S. Orange; Nabil Ahmed
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that are redirected to single tumor antigens. Given the heterogeneous expression of antigens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape and improve the antitumor activity of T cells. Here, we created a CAR that joins a HER2-binding scFv and an IL13Rα2-binding IL-13 mutein to make a tandem CAR exodomain (TanCAR) and a CD28.ζ endodomain. We determined that patient TanCAR T cells showed distinct binding to HER2 or IL13Rα2 and had the capability to lyse autologous glioblastoma. TanCAR T cells exhibited activation dynamics that were comparable to those of single CAR T cells upon encounter of HER2 or IL13Rα2. We observed that TanCARs engaged HER2 and IL13Rα2 simultaneously by inducing HER2-IL13Rα2 heterodimers, which promoted superadditive T cell activation when both antigens were encountered concurrently. TanCAR T cell activity was more sustained but not more exhaustible than that of T cells that coexpressed a HER2 CAR and an IL13Rα2 CAR, T cells with a unispecific CAR, or a pooled product. In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival. Thus, TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.
Molecular Therapy | 2016
Giedre Krenciute; Simone Krebs; David Torres; Meng Fen Wu; Hao Liu; Gianpietro Dotti; Xiao-Nan Li; Maciej S. Lesniak; Irina V. Balyasnikova; Stephen Gottschalk
Immunotherapy with T cells expressing chimeric antigen receptors (CARs) is an attractive approach to improve outcomes for patients with glioblastoma (GBM). IL13Rα2 is expressed at a high frequency in GBM but not in normal brain, making it a promising CAR T-cell therapy target. IL13Rα2-specific CARs generated up to date contain mutated forms of IL13 as an antigen-binding domain. While these CARs target IL13Rα2, they also recognize IL13Rα1, which is broadly expressed. To overcome this limitation, we constructed a panel of IL13Rα2-specific CARs that contain the IL13Rα2-specific single-chain variable fragment (scFv) 47 as an antigen binding domain, short or long spacer regions, a transmembrane domain, and endodomains derived from costimulatory molecules and CD3.ζ (IL13Rα2-CARs). IL13Rα2-CAR T cells recognized IL13Rα2-positive target cells in coculture and cytotoxicity assays with no cross-reactivity to IL13Rα1. However, only IL13Rα2-CAR T cells with a short spacer region produced IL2 in an antigen-dependent fashion. In vivo, T cells expressing IL13Rα2-CARs with short spacer regions and CD28.ζ, 41BB.ζ, and CD28.OX40.ζ endodomains had potent anti-glioma activity conferring a significant survival advantage in comparison to mice that received control T cells. Thus, IL13Rα2-CAR T cells hold the promise to improve current IL13Rα2-targeted immunotherapy approaches for GBM and other IL13Rα2-positive malignancies.
Cytotherapy | 2014
Simone Krebs; Kevin Chow; Zhongzhen Yi; Tania Rodriguez-Cruz; Meenakshi Hegde; Claudia Gerken; Nabil Ahmed; Stephen Gottschalk
BACKGROUND AIMS Outcomes for patients with glioblastoma remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL) 13Rα2, human epidermal growth factor receptor 2, epidermal growth factor variant III or erythropoietin-producing hepatocellular carcinoma A2 has shown promise for the treatment of glioma in preclinical models. On the basis of IL13Rα2 immunotoxins that contain IL13 molecules with one or two amino acid substitutions (IL13 muteins) to confer specificity to IL13Rα2, investigators have constructed CARS with IL13 muteins as antigen-binding domains. Whereas the specificity of IL13 muteins in the context of immunotoxins is well characterized, limited information is available for CAR T cells. METHODS We constructed four second-generation CARs with IL13 muteins with one or two amino acid substitutions, and evaluated the effector function of IL13-mutein CAR T cells in vitro and in vivo. RESULTS T cells expressing all four CARs recognized IL13Rα1 or IL13Rα2 recombinant protein in contrast to control protein (IL4R) as judged by interferon-γ production. IL13 protein produced significantly more IL2, indicating that IL13 mutein-CAR T cells have a higher affinity to IL13Rα2 than to IL13Rα1. In cytotoxicity assays, CAR T cells killed IL13Rα1- and/or IL13Rα2-positive cells in contrast to IL13Rα1- and IL13Rα2-negative controls. Although we observed no significant differences between IL13 mutein-CAR T cells in vitro, only T cells expressing IL13 mutein-CARs with an E13K amino acid substitution had anti-tumor activity in vivo that resulted in a survival advantage of treated animals. CONCLUSIONS Our study highlights that the specificity/avidity of ligands is context-dependent and that evaluating CAR T cells in preclinical animal model is critical to assess their potential benefit.
Frontiers in Oncology | 2013
Simone Krebs; Tania Rodriguez-Cruz; Christopher DeRenzo; Stephen Gottschalk
Despite advances in surgical procedures, radiation, and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressive microenvironment. The advent of gene transfer has allowed the rapid generation of antigen-specific T cells as well as T cells with enhanced effector function. Here we review recent advances in the field of cell therapy with genetically modified T cells and how these advances might improve outcomes for patients with GBM in the future.
Journal for ImmunoTherapy of Cancer | 2015
Giedre Krenciute; Simone Krebs; David Torres; Gianpietro Dotti; Maciej S. Lesniak; Irina V. Balyasnikova; Stephen Gottschalk
Meeting abstracts The goal of this project is to develop T cells that express chimeric antigen receptors (CARs) as an effective immunotherapy for glioblastoma (GBM), the most aggressive, primary brain tumor in humans, which outcome remains poor. IL13Rα2 is aberrantly expressed in GBM and therefore
Cytotherapy | 2014
Simone Krebs; Stephen Gottschalk
In this issue of Cytotherapy, Lopez-Ornelas et al. present an elegant study using genetically modified neural stem cells (NSCs)as therapy forglioblastoma(GBM)(1).They demonstrate thatNSCs, geneticallymodified to express a soluble form of growth arrest specific 1 (Gas1) under the transcriptional control of an inducible promoter, migrate to glioma in vivo and have antitumor effects in vivo. GBM is the most aggressive, primary brain tumor in humans (2). Despite multimodal therapy regimens, consisting of surgery, radiotherapy and chemotherapy, outcome has only marginally improved within the past decades, and most patients die of their disease within 2 years of diagnosis (2). Thus new therapeutic approaches are urgently needed, and several approaches are actively being explored including targeting oncogenic pathways with small molecule inhibitors, immunotherapies, and stem cell therapies (3). Among stem cells, NSCs and mesenchymal stem cells (MSCs) are a major focus of research because of their inherent ability to migrate to glioma sites (4,5).These cells canbe geneticallymodified to produce (i) high levels of prodrug-activating enzymes to increase the local concentration of active chemotherapeutic agents (6), (ii) immunomodulatory cytokines (7), (iii) molecules that induce apoptosis or cell cycle arrest (8), (iv) enzymes that modulate the tumor microenvironment (9), and (v) antibodies (10). In addition, NSCs andMSCs can be engineered to deliver oncolytic viruses (11,12)ornanoparticles to tumorsites (Figure1) (13,14). Examples of enzyme/prodrug therapy includes the delivery of cytosine deaminase, which converts 5fluorocytosine to the active chemotherapeutic agent 5-fluorouracil, or the delivery of carboxylesterase (CE), which activates irinotecan to SN-38, a potent topoisomerase I inhibitor (6,15), NSCs delivering CE in combination with irinotecan is currently being
Journal of Clinical Oncology | 2017
Meenakshi Hegde; Amanda Wakefield; Vita S. Brawley; Zakaria Grada; Tiara Byrd; Kevin Chow; Simone Krebs; Helen E. Heslop; Stephen Gottschalk; Eric Yvon; Nabil Ahmed
Neuro-oncology | 2016
Kevin Bielamowicz; Kristen Fousek; Tiara Byrd; Malani Mukherjee; Nikita Aware; Kevin Chow; Simone Krebs; Zhongzhen Yi; Gianpietro Dotti; Pavel Sumazin; Stephen Gottschalk; Meena Hegde; Nabil Ahmed
Neuro-oncology | 2015
Giedre Krenciute; Simone Krebs; David Torres; Maciej S. Lesniak; Irina V. Balyasnikova; Stephen Gottschalk